Adlai Nortye Ltd.
Status: Publicly traded
Direct answer
Adlai Nortye Ltd. is publicly traded on NASDAQ under the ticker ANL.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also...
Can you invest in Adlai Nortye Ltd.?
Yes. Adlai Nortye Ltd. is publicly traded on NASDAQ under the ticker ANL.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Adlai Nortye Ltd.
Detailed equity research is provided by MarketSnap.